

8. Literaturverzeichnis

1. Ware, J., et al., *Health and developmental outcomes of a surfactant controlled trial: follow-up at 2 years*. Pediatrics, 1990. **85**(6): p. 1103-7.
2. Crowley, P., I. Chalmers, and M.J. Keirse, *The effects of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials*. Br J Obstet Gynaecol, 1990. **97**(1): p. 11-25.
3. Schwartz, R.M., et al., *Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 g*. N Engl J Med, 1994. **330**(21): p. 1476-80.
4. Hack, M., et al., *Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Network*. Pediatrics, 1991. **87**(5): p. 587-97.
5. Blaymore-Bier, J., et al., *Outcome of extremely low-birth-weight infants: 1980-1990*. Acta Paediatr, 1994. **83**(12): p. 1244-8.
6. Tin, W., U. Wariyar, and E. Hey, *Changing prognosis for babies of less than 28 weeks' gestation in the north of England between 1983 and 1994*. Northern Neonatal Network. Bmj, 1997. **314**(7074): p. 107-11.
7. Bregman, J., *Developmental outcome in very low birthweight infants. Current status and future trends*. Pediatr Clin North Am, 1998. **45**(3): p. 673-90.
8. Halsey, C.L., M.F. Collin, and C.L. Anderson, *Extremely low-birth-weight children and their peers. A comparison of school-age outcomes*. Arch Pediatr Adolesc Med, 1996. **150**(8): p. 790-4.
9. Berkowitz, G.S. and E. Papiernik, *Epidemiology of preterm birth*. Epidemiol Rev, 1993. **15**(2): p. 414-43.
10. Emsley, H.C., et al., *Increased survival and deteriorating developmental outcome in 23 to 25 week old gestation infants, 1990-4 compared with 1984-9*. Arch Dis Child Fetal Neonatal Ed, 1998. **78**(2): p. F99-104.
11. Vohr, B.R., et al., *Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993-1994*. Pediatrics, 2000. **105**(6): p. 1216-26.
12. Marlow, N., et al., *Neurologic and developmental disability at six years of age after extremely preterm birth*. N Engl J Med, 2005. **352**(1): p. 9-19.
13. Taeusch, H.W., and Ballard, R. A., *Avery's Diseases of the Newborn*. 7th ed. Saunders, Philadelphia, 1998.
14. Iwamoto, H.S., D. Teitel, and A.M. Rudolph, *Effects of birth-related events on blood flow distribution*. Pediatr Res, 1987. **22**(6): p. 634-40.
15. Saugstad, O.D., *Chronic lung disease: oxygen dogma revisited*. Acta Paediatr, 2001. **90**(2): p. 113-5.
16. Gibson, D.L., et al., *Retinopathy of prematurity-induced blindness: birth weight-specific survival and the new epidemic*. Pediatrics, 1990. **86**(3): p. 405-12.
17. Downes, J.J., *Resuscitation and intensive care of the newborn infant*. Int Anesthesiol Clin, 1968. **6**(3): p. 911-53.
18. Cockburn, F., *Resuscitation of the newborn*. Br J Anaesth, 1971. **43**(9): p. 886-902.
19. Saugstad, O.D., *Is oxygen more toxic than currently believed?* Pediatrics, 2001. **108**(5): p. 1203-5.
20. Silverman, W.A., *Retinopathy of prematurity: oxygen dogma challenged*. Arch Dis Child, 1982. **57**(10): p. 731-3.
21. Bolton, D.P. and K.W. Cross, *Further observations on cost of preventing retrolental fibroplasia*. Lancet, 1974. **1**(7855): p. 445-8.

22. Howell M, F.P., *The paradoxes of a small American disaster*. The Beetle of Aphrodite. New York: Random House, 1985: p. 210-236.
23. Bagenholm, R., et al., *Free radicals are formed in the brain of fetal sheep during reperfusion after cerebral ischemia*. *Pediatr Res*, 1998. **43**(2): p. 271-5.
24. Kondo, M., et al., *Chemiluminescence because of the production of reactive oxygen species in the lungs of newborn piglets during resuscitation periods after asphyxiation load*. *Pediatr Res*, 2000. **47**(4 Pt 1): p. 524-7.
25. Suzuki, Y.J., H.J. Forman, and A. Sevanian, *Oxidants as stimulators of signal transduction*. *Free Radic Biol Med*, 1997. **22**(1-2): p. 269-85.
26. Weinberger, B., et al., *Oxygen toxicity in premature infants*. *Toxicol Appl Pharmacol*, 2002. **181**(1): p. 60-7.
27. Vento M, G.-S.F., Vina J, et al., *The use of room air ventilation enhances the establishment of a sustained spontaneous respiratory pattern after perinatal asphyxia*. *Pediatr Res*, 2000. **47**: p. 438.
28. Del Maestro, R., et al., *Free radicals as mediators of tissue injury*. *Acta Physiol Scand Suppl*, 1980. **492**: p. 43-57.
29. O'Donovan, D.J. and C.J. Fernandes, *Mitochondrial glutathione and oxidative stress: implications for pulmonary oxygen toxicity in premature infants*. *Mol Genet Metab*, 2000. **71**(1-2): p. 352-8.
30. Gladstone, I.M., Jr. and R.L. Levine, *Oxidation of proteins in neonatal lungs*. *Pediatrics*, 1994. **93**(5): p. 764-8.
31. Jankov, R.P., A. Negus, and A.K. Tanswell, *Antioxidants as therapy in the newborn: some words of caution*. *Pediatr Res*, 2001. **50**(6): p. 681-7.
32. Li, N. and M. Karin, *Is NF-kappaB the sensor of oxidative stress?* *Faseb J*, 1999. **13**(10): p. 1137-43.
33. Frank, L. and I.R. Sosenko, *Failure of premature rabbits to increase antioxidant enzymes during hyperoxic exposure: increased susceptibility to pulmonary oxygen toxicity compared with term rabbits*. *Pediatr Res*, 1991. **29**(3): p. 292-6.
34. Frank, L. and E.E. Groseclose, *Preparation for birth into an O₂-rich environment: the antioxidant enzymes in the developing rabbit lung*. *Pediatr Res*, 1984. **18**(3): p. 240-4.
35. Asikainen, T.M., et al., *Expression and developmental profile of antioxidant enzymes in human lung and liver*. *Am J Respir Cell Mol Biol*, 1998. **19**(6): p. 942-9.
36. Freeman, B.A. and J.D. Crapo, *Hyperoxia increases oxygen radical production in rat lungs and lung mitochondria*. *J Biol Chem*, 1981. **256**(21): p. 10986-92.
37. Sullivan, J.L. and R.B. Newton, *Serum antioxidant activity in neonates*. *Arch Dis Child*, 1988. **63**(7 Spec No): p. 748-50.
38. Frank, L., *Antioxidants, nutrition, and bronchopulmonary dysplasia*. *Clin Perinatol*, 1992. **19**(3): p. 541-62.
39. Lindeman, J.H., et al., *The total free radical trapping ability of cord blood plasma in preterm and term babies*. *Pediatr Res*, 1989. **26**(1): p. 20-4.
40. Frank, L. and I.R. Sosenko, *Development of lung antioxidant enzyme system in late gestation: possible implications for the prematurely born infant*. *J Pediatr*, 1987. **110**(1): p. 9-14.
41. Frank, L. and I.R. Sosenko, *Prenatal development of lung antioxidant enzymes in four species*. *J Pediatr*, 1987. **110**(1): p. 106-10.
42. Saugstad, O.D., T. Rootwelt, and O. Aalen, *Resuscitation of asphyxiated newborn infants with room air or oxygen: an international controlled trial: the Resair 2 study*. *Pediatrics*, 1998. **102**(1): p. e1.
43. Aiello, L.P., *Vascular endothelial growth factor and the eye. Past, present and future*. *Arch Ophthalmol*, 1996. **114**(10): p. 1252-4.

44. Phelps, D.L., *Retinopathy of prematurity*. Curr Probl Pediatr, 1992. **22**(8): p. 349-71.
45. Davis, J.M., et al., *Differential effects of oxygen and barotrauma on lung injury in the neonatal piglet*. Pediatr Pulmonol, 1991. **10**(3): p. 157-63.
46. Groneck, P. and C.P. Speer, *Inflammatory mediators and bronchopulmonary dysplasia*. Arch Dis Child Fetal Neonatal Ed, 1995. **73**(1): p. F1-3.
47. Yoon, B.H., et al., *A systemic fetal inflammatory response and the development of bronchopulmonary dysplasia*. Am J Obstet Gynecol, 1999. **181**(4): p. 773-9.
48. Saugstad, O.D., *Chronic lung disease: the role of oxidative stress*. Biol Neonate, 1998. **74 Suppl 1**: p. 21-8.
49. Bucher, J.R. and R.J. Roberts, *The development of the newborn rat lung in hyperoxia: a dose-response study of lung growth, maturation, and changes in antioxidant enzyme activities*. Pediatr Res, 1981. **15**(7): p. 999-1008.
50. Han, R.N., et al., *Changes in structure, mechanics, and insulin-like growth factor-related gene expression in the lungs of newborn rats exposed to air or 60% oxygen*. Pediatr Res, 1996. **39**(6): p. 921-9.
51. Simic, M.G. and K.A. Taylor, *Introduction to peroxidation and antioxidation mechanisms*. Basic Life Sci, 1988. **49**: p. 1-10.
52. Saugstad, O.D., *Bronchopulmonary dysplasia-oxidative stress and antioxidants*. Semin Neonatol, 2003. **8**(1): p. 39-49.
53. Saugstad, O.D., *Oxygen toxicity in the neonatal period*. Acta Paediatr Scand, 1990. **79**(10): p. 881-92.
54. Wilborn, A.M., L.B. Evers, and A.T. Canada, *Oxygen toxicity to the developing lung of the mouse: role of reactive oxygen species*. Pediatr Res, 1996. **40**(2): p. 225-32.
55. Pierce, M.R. and E. Bancalari, *The role of inflammation in the pathogenesis of bronchopulmonary dysplasia*. Pediatr Pulmonol, 1995. **19**(6): p. 371-8.
56. Saugstad, O.D., *Update on oxygen radical disease in neonatology*. Curr Opin Obstet Gynecol, 2001. **13**(2): p. 147-53.
57. Inder, T.E. and J.J. Volpe, *Mechanisms of perinatal brain injury*. Semin Neonatol, 2000. **5**(1): p. 3-16.
58. Gerstner, B., et al., *Maturation-dependent oligodendrocyte apoptosis caused by hyperoxia*. J Neurosci Res, 2006. **84**(2): p. 306-15.
59. Collins, M.P., et al., *Hypocapnia and other ventilation-related risk factors for cerebral palsy in low birth weight infants*. Pediatr Res, 2001. **50**(6): p. 712-9.
60. Gabbita, S.P., M.A. Lovell, and W.R. Markesbery, *Increased nuclear DNA oxidation in the brain in Alzheimer's disease*. J Neurochem, 1998. **71**(5): p. 2034-40.
61. Mecocci, P., U. MacGarvey, and M.F. Beal, *Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease*. Ann Neurol, 1994. **36**(5): p. 747-51.
62. Polidori, M.C., et al., *Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex*. Neurosci Lett, 1999. **272**(1): p. 53-6.
63. Forster, M.J., et al., *Age-related losses of cognitive function and motor skills in mice are associated with oxidative protein damage in the brain*. Proc Natl Acad Sci U S A, 1996. **93**(10): p. 4765-9.
64. Jacobson, M.D., *Reactive oxygen species and programmed cell death*. Trends Biochem Sci, 1996. **21**(3): p. 83-6.
65. Vexler, Z.S. and D.M. Ferriero, *Molecular and biochemical mechanisms of perinatal brain injury*. Semin Neonatol, 2001. **6**(2): p. 99-108.
66. Ahdab-Barmada, M., et al., *Hyperoxia produces neuronal necrosis in the rat*. J Neuropathol Exp Neurol, 1986. **45**(3): p. 233-46.

67. Tagliatalata, G., J.R. Perez-Polo, and D.K. Rassin, *Induction of apoptosis in the CNS during development by the combination of hyperoxia and inhibition of glutathione synthesis*. Free Radic Biol Med, 1998. **25**(8): p. 936-42.
68. Katoh, S., et al., *The rescuing effect of nerve growth factor is the result of up-regulation of bcl-2 in hyperoxia-induced apoptosis of a subclone of pheochromocytoma cells, PC12h*. Neurosci Lett, 1997. **232**(2): p. 71-4.
69. Felderhoff-Mueser, U., et al., *Oxygen causes cell death in the developing brain*. Neurobiol Dis, 2004. **17**(2): p. 273-82.
70. Kutzsche, S., et al., *Effects of hypoxia and reoxygenation with 21% and 100%-oxygen on cerebral nitric oxide concentration and microcirculation in newborn piglets*. Biol Neonate, 1999. **76**(3): p. 153-67.
71. Rozycki, H.J., P.G. Comber, and T.F. Huff, *Cytokines and oxygen radicals after hyperoxia in preterm and term alveolar macrophages*. Am J Physiol Lung Cell Mol Physiol, 2002. **282**(6): p. L1222-8.
72. Rozycki, H.J., *Bronchoalveolar interleukin-1 beta in infants on day 1 of life*. South Med J, 1994. **87**(10): p. 991-6.
73. Allan, S.M. and N.J. Rothwell, *Cytokines and acute neurodegeneration*. Nat Rev Neurosci, 2001. **2**(10): p. 734-44.
74. Berger, A., et al., *Microbial invasion of the amniotic cavity at birth is associated with adverse short-term outcome of preterm infants*. J Perinat Med, 2003. **31**(2): p. 115-21.
75. Sonntag, J., et al., *Effect of C1-inhibitor in a rat model of necrotizing enterocolitis*. Biol Neonate, 1999. **76**(4): p. 235-41.
76. Yoon, B.H., et al., *Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions, and cerebral palsy*. Am J Obstet Gynecol, 1997. **177**(1): p. 19-26.
77. Gomez, R., et al., *Pathogenesis of preterm labor and preterm premature rupture of membranes associated with intraamniotic infection*. Infect Dis Clin North Am, 1997. **11**(1): p. 135-76.
78. Pierce, B.T., et al., *The effects of hypoxia and hyperoxia on fetal-placental vascular tone and inflammatory cytokine production*. Am J Obstet Gynecol, 2001. **185**(5): p. 1068-72.
79. Leviton, A., *Preterm birth and cerebral palsy: is tumor necrosis factor the missing link?* Dev Med Child Neurol, 1993. **35**(6): p. 553-8.
80. Leviton, A., et al., *Maternal infection, fetal inflammatory response, and brain damage in very low birth weight infants*. Developmental Epidemiology Network Investigators. Pediatr Res, 1999. **46**(5): p. 566-75.
81. Dammann, O. and A. Leviton, *Infection remote from the brain, neonatal white matter damage, and cerebral palsy in the preterm infant*. Semin Pediatr Neurol, 1998. **5**(3): p. 190-201.
82. Rothwell, N., S. Allan, and S. Toulmond, *The role of interleukin 1 in acute neurodegeneration and stroke: pathophysiological and therapeutic implications*. J Clin Invest, 1997. **100**(11): p. 2648-52.
83. Rabuffetti, M., et al., *Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines*. J Neurosci, 2000. **20**(12): p. 4398-404.
84. Dinarello, C.A. and G. Fantuzzi, *Interleukin-18 and host defense against infection*. J Infect Dis, 2003. **187** Suppl 2: p. S370-84.
85. Lindberg, C., et al., *Neuronal expression of caspase-1 immunoreactivity in the rat central nervous system*. J Neuroimmunol, 2004. **146**(1-2): p. 99-113.

86. Liu, X.H., et al., *Mice deficient in interleukin-1 converting enzyme are resistant to neonatal hypoxic-ischemic brain damage*. J Cereb Blood Flow Metab, 1999. **19**(10): p. 1099-108.
87. Rothwell, N.J. and S.J. Hopkins, *Cytokines and the nervous system II: Actions and mechanisms of action*. Trends Neurosci, 1995. **18**(3): p. 130-6.
88. Dinarello, C.A. and R.C. Thompson, *Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro*. Immunol Today, 1991. **12**(11): p. 404-10.
89. Dinarello, C.A., *Biologic basis for interleukin-1 in disease*. Blood, 1996. **87**(6): p. 2095-147.
90. Farrar, W.L., et al., *Visualization and characterization of interleukin 1 receptors in brain*. J Immunol, 1987. **139**(2): p. 459-63.
91. Wang, C.X. and A. Shuaib, *Involvement of inflammatory cytokines in central nervous system injury*. Prog Neurobiol, 2002. **67**(2): p. 161-72.
92. Lechan, R.M., et al., *Immunoreactive interleukin-1 beta localization in the rat forebrain*. Brain Res, 1990. **514**(1): p. 135-40.
93. Hopkins, S.J. and N.J. Rothwell, *Cytokines and the nervous system. I: Expression and recognition*. Trends Neurosci, 1995. **18**(2): p. 83-8.
94. Benveniste, E.N., *Cytokines: influence on glial cell gene expression and function*. Chem Immunol, 1997. **69**: p. 31-75.
95. Rothwell, N.J. and G. Luheshi, *Pharmacology of interleukin-1 actions in the brain*. Adv Pharmacol, 1994. **25**: p. 1-20.
96. Thornberry, N.A., et al., *A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes*. Nature, 1992. **356**(6372): p. 768-74.
97. Nicholson, D.W. and N.A. Thornberry, *Caspases: killer proteases*. Trends Biochem Sci, 1997. **22**(8): p. 299-306.
98. Sims, J.E., et al., *Interleukin 1 signaling occurs exclusively via the type I receptor*. Proc Natl Acad Sci U S A, 1993. **90**(13): p. 6155-9.
99. Gabellec, M.M., et al., *Expression of interleukin-1 genes and interleukin-1 receptors in the mouse brain after hippocampal injury*. Neurosci Res, 1999. **33**(4): p. 251-60.
100. Allan, S.M., *The role of pro- and antiinflammatory cytokines in neurodegeneration*. Ann N Y Acad Sci, 2000. **917**: p. 84-93.
101. Spalletta, G., et al., *The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines*. Mol Psychiatry, 2006.
102. Gemma, C., et al., *Improvement of memory for context by inhibition of caspase-1 in aged rats*. Eur J Neurosci, 2005. **22**(7): p. 1751-6.
103. Bilbo, S.D., et al., *Neonatal infection-induced memory impairment after lipopolysaccharide in adulthood is prevented via caspase-1 inhibition*. J Neurosci, 2005. **25**(35): p. 8000-9.
104. Nakamura, K., et al., *Endotoxin-induced serum factor that stimulates gamma interferon production*. Infect Immun, 1989. **57**(2): p. 590-5.
105. Dinarello, C.A., *Interleukin-18*. Methods, 1999. **19**(1): p. 121-32.
106. Torigoe, K., et al., *Purification and characterization of the human interleukin-18 receptor*. J Biol Chem, 1997. **272**(41): p. 25737-42.
107. Parnet, P., et al., *IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP*. J Biol Chem, 1996. **271**(8): p. 3967-70.
108. Reznikov, L.L., et al., *IL-18 binding protein increases spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-gamma*. Proc Natl Acad Sci U S A, 2000. **97**(5): p. 2174-9.

109. Born, T.L., et al., *Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling*. J Biol Chem, 1998. **273**(45): p. 29445-50.
110. Greenfeder, S.A., et al., *Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex*. J Biol Chem, 1995. **270**(23): p. 13757-65.
111. Andre, R., et al., *Identification of a truncated IL-18R beta mRNA: a putative regulator of IL-18 expressed in rat brain*. J Neuroimmunol, 2003. **145**(1-2): p. 40-5.
112. Culhane, A.C., et al., *Cloning of rat brain interleukin-18 cDNA*. Mol Psychiatry, 1998. **3**(4): p. 362-6.
113. Hedtjarn, M., et al., *White matter injury in the immature brain: role of interleukin-18*. Neurosci Lett, 2005. **373**(1): p. 16-20.
114. Yoshimoto, T., et al., *IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production*. J Immunol, 1998. **161**(7): p. 3400-7.
115. Lauw, F.N., et al., *Interleukin-12 induces sustained activation of multiple host inflammatory mediator systems in chimpanzees*. J Infect Dis, 1999. **179**(3): p. 646-52.
116. Okamura, H., et al., *Cloning of a new cytokine that induces IFN-gamma production by T cells*. Nature, 1995. **378**(6552): p. 88-91.
117. Matsumoto, S., et al., *Interleukin-18 activates NF-kappaB in murine T helper type 1 cells*. Biochem Biophys Res Commun, 1997. **234**(2): p. 454-7.
118. Puren, A.J., et al., *Interleukin-18 (IFN-gamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells*. J Clin Invest, 1998. **101**(3): p. 711-21.
119. Yatsiv, I., et al., *Elevated intracranial IL-18 in humans and mice after traumatic brain injury and evidence of neuroprotective effects of IL-18-binding protein after experimental closed head injury*. J Cereb Blood Flow Metab, 2002. **22**(8): p. 971-8.
120. Jander, S., M. Schroeter, and G. Stoll, *Interleukin-18 expression after focal ischemia of the rat brain: association with the late-stage inflammatory response*. J Cereb Blood Flow Metab, 2002. **22**(1): p. 62-70.
121. Dinarello, C.A., *Interleukin-18 and the treatment of rheumatoid arthritis*. Rheum Dis Clin North Am, 2004. **30**(2): p. 417-34, ix.
122. Vossenkamper, A., et al., *Both IL-12 and IL-18 contribute to small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii, but IL-12 is dominant over IL-18 in parasite control*. Eur J Immunol, 2004. **34**(11): p. 3197-207.
123. Furlan, R., et al., *Caspase-1 regulates the inflammatory process leading to autoimmune demyelination*. J Immunol, 1999. **163**(5): p. 2403-9.
124. Zwijnenburg, P.J., et al., *Interleukin-18 gene-deficient mice show enhanced defense and reduced inflammation during pneumococcal meningitis*. J Neuroimmunol, 2003. **138**(1-2): p. 31-7.
125. von Giesen, H.J., et al., *Serum and cerebrospinal fluid levels of interleukin-18 in human immunodeficiency virus type 1-associated central nervous system disease*. J Neurovirol, 2004. **10**(6): p. 383-6.
126. Hagberg, H., C. Mallard, and B. Jacobsson, *Role of cytokines in preterm labour and brain injury*. Bjog, 2005. **112 Suppl 1**: p. 16-8.
127. Yang, Y., et al., *Regulation of IL-18 expression by CRH in mouse microglial cells*. Immunol Lett, 2005. **98**(2): p. 291-6.
128. Liu, Y.P., H.I. Lin, and S.F. Tzeng, *Tumor necrosis factor-alpha and interleukin-18 modulate neuronal cell fate in embryonic neural progenitor culture*. Brain Res, 2005. **1054**(2): p. 152-8.
129. Suzuki, N., et al., *Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4*. Nature, 2002. **416**(6882): p. 750-6.

130. Li, S., et al., *IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase*. Proc Natl Acad Sci U S A, 2002. **99**(8): p. 5567-72.
131. Malinin, N.L., et al., *MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1*. Nature, 1997. **385**(6616): p. 540-4.
132. DiDonato, J.A., et al., *A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB*. Nature, 1997. **388**(6642): p. 548-54.
133. Huang, F.P., et al., *Early NFkappaB activation is inhibited during focal cerebral ischemia in interleukin-1beta-converting enzyme deficient mice*. J Neurosci Res, 2003. **73**(5): p. 698-707.
134. Novick, D., et al., *Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response*. Immunity, 1999. **10**(1): p. 127-36.
135. Kim, S.H., et al., *Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18*. Proc Natl Acad Sci U S A, 2000. **97**(3): p. 1190-5.
136. Dobbing, J., *The later growth of the brain and its vulnerability*. Pediatrics, 1974. **53**(1): p. 2-6.
137. Dobbing, J. and J. Sands, *Head circumference, biparietal diameter and brain growth in fetal and postnatal life*. Early Hum Dev, 1978. **2**(1): p. 81-7.
138. Dobbing, J. and J. Sands, *Comparative aspects of the brain growth spurt*. Early Hum Dev, 1979. **3**(1): p. 79-83.
139. Asimiadou, S., et al., *Protection with estradiol in developmental models of apoptotic neurodegeneration*. Ann Neurol, 2005. **58**(2): p. 266-76.
140. Manthey, D., et al., *Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain*. Exp Neurol, 2005. **193**(2): p. 497-503.
141. Bittigau, P., et al., *Apoptotic neurodegeneration in the context of traumatic injury to the developing brain*. Exp Toxicol Pathol, 2004. **56**(1-2): p. 83-9.
142. Kerr, J.F., A.H. Wyllie, and A.R. Currie, *Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics*. Br J Cancer, 1972. **26**(4): p. 239-57.
143. Ishimaru, M.J., et al., *Distinguishing excitotoxic from apoptotic neurodegeneration in the developing rat brain*. J Comp Neurol, 1999. **408**(4): p. 461-76.
144. Yuan, J. and B.A. Yankner, *Apoptosis in the nervous system*. Nature, 2000. **407**(6805): p. 802-9.
145. Suzuki, N., et al., *IL-1 receptor-associated kinase 4 is essential for IL-18-mediated NK and Th1 cell responses*. J Immunol, 2003. **170**(8): p. 4031-5.
146. DeOlmos, J., *An improved cupric-silver method for impregnation of axonal and terminal degeneration*. Brain Res, 1971. **33**(523-529).
147. DeOlmos, J., *The projection field of the striata terminalis in the rat brain. An experimental study*. J Comp Neurol, 1972. **146**(303-334).
148. Ishimaru, M. and C. Ikonomidou, *Distinguishing exitotoxic from apoptotic neurodegeneration in the developing rat brain*. J. Comp. Neurol., 1999. **408**(461-476).
149. Schmued, L., *Fluoro-Jade B: a high affinity floureszent marker for the localisation of neuronal degeneration*. Brain Res, 2000. **874**(123-130).
150. Shi, S.R., R.J. Cote, and C.R. Taylor, *Antigen retrieval immunohistochemistry: past, present, and future*. J Histochem Cytochem, 1997. **45**(3): p. 327-43.
151. West, M., *Unbiased stereological estimation of the number of neurons in the human hippocampus*. J Comp Neurol, 1990. **296**(1)(1-22).
152. Bittigau, P., *Apoptotic neurodegeneration following trauma is markedly enhanced in the immature brain*. Ann Neurol, 1999. **45**(724-735).
153. Chomczynski, P. and N. Sacchi, *Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction*. Anal Biochem, 1987. **162**(1): p. 156-9.

154. Kaiser, A.D. and D.S. Hogness, *The transformation of Escherichia coli with deoxyribonucleic acid isolated from bacteriophage lambda-dg*. J Mol Biol, 1960. **2**: p. 392-415.
155. Spanakis, E., *Problems related to the interpretation of autoradiographic data on gene expression using common constitutive transcripts as controls*. Nucleic Acids Res, 1993. **21**(16): p. 3809-19.
156. Lohmann, J., H. Schickle, and T.C. Bosch, *REN display, a rapid and efficient method for nonradioactive differential display and mRNA isolation*. Biotechniques, 1995. **18**(2): p. 200-2.
157. Laemmli, U.K., *Cleavage of structural proteins during the assembly of the head of bacteriophage T4*. Nature, 1970. **227**(5259): p. 680-5.
158. Kuida, K., et al., *Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme*. Science, 1995. **267**(5206): p. 2000-3.
159. Chu, G.L. and Y. Xin, *[Expression of caspase - 1 after hypoxic-ischemic brain damage]*. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 2005. **17**(3): p. 183-5.
160. Xu, H., et al., *Attenuation of hypoxia-ischemia-induced monocyte chemoattractant protein-1 expression in brain of neonatal mice deficient in interleukin-1 converting enzyme*. Brain Res Mol Brain Res, 2001. **90**(1): p. 57-67.
161. Hara, H., et al., *Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage*. Proc Natl Acad Sci U S A, 1997. **94**(5): p. 2007-12.
162. Fink, K.B., et al., *Reduction of post-traumatic brain injury and free radical production by inhibition of the caspase-1 cascade*. Neuroscience, 1999. **94**(4): p. 1213-8.
163. Park, H.J., et al., *Increased expression of IL-18 in cutaneous graft-versus-host disease*. Immunol Lett, 2004. **95**(1): p. 57-61.
164. Faubel, S. and C.L. Edelstein, *Caspases as drug targets in ischemic organ injury*. Curr Drug Targets Immune Endocr Metabol Disord, 2005. **5**(3): p. 269-87.
165. Yang, W., et al., *MX1013, a dipeptide caspase inhibitor with potent in vivo antiapoptotic activity*. Br J Pharmacol, 2003. **140**(2): p. 402-12.
166. Hedtjarn, M., et al., *Interleukin-18 involvement in hypoxic-ischemic brain injury*. J Neurosci, 2002. **22**(14): p. 5910-9.
167. Rothwell, N., *Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential*. Brain Behav Immun, 2003. **17**(3): p. 152-7.
168. Hagberg, H., et al., *Enhanced expression of interleukin (IL)-1 and IL-6 messenger RNA and bioactive protein after hypoxia-ischemia in neonatal rats*. Pediatr Res, 1996. **40**(4): p. 603-9.
169. Cai, Z., et al., *Cytokine induction in fetal rat brains and brain injury in neonatal rats after maternal lipopolysaccharide administration*. Pediatr Res, 2000. **47**(1): p. 64-72.
170. Dommergues, M.A., et al., *Proinflammatory cytokines and interleukin-9 exacerbate excitotoxic lesions of the newborn murine neopallium*. Ann Neurol, 2000. **47**(1): p. 54-63.
171. Pang, Y., Z. Cai, and P.G. Rhodes, *Disturbance of oligodendrocyte development, hypomyelination and white matter injury in the neonatal rat brain after intracerebral injection of lipopolysaccharide*. Brain Res Dev Brain Res, 2003. **140**(2): p. 205-14.
172. Rothwell, N.J., *Cytokines and acute neurodegeneration*. Mol Psychiatry, 1997. **2**(2): p. 120-1.
173. Mao, D.A., et al., *[Role of caspase-1 and cytokines activated by caspase-1 in brain injury of the developing rats following recurrent seizures]*. Zhongguo Dang Dai Er Ke Za Zhi, 2006. **8**(2): p. 133-6.

174. Xin, Y. and G.L. Chu, [*Expression of and relationship between caspase-1 and interleukin-18 mRNA in brain tissue of hypoxic-ischemic neonatal rats*]. Zhonghua Er Ke Za Zhi, 2005. **43**(8): p. 568-71.
175. Schmidt, O.I., et al., *Tumor necrosis factor-mediated inhibition of interleukin-18 in the brain: a clinical and experimental study in head-injured patients and in a murine model of closed head injury*. J Neuroinflammation, 2004. **1**(1): p. 13.
176. Zhang, Y., C. Wang, and M. Sun, *C6 glioma cells retrovirally engineered to express IL-18 and Fas exert FasL-dependent cytotoxicity against glioma formation*. Biochem Biophys Res Commun, 2004. **325**(4): p. 1240-5.
177. Koennings, S., et al., *In vitro investigation of lipid implants as a controlled release system for interleukin-18*. Int J Pharm, 2006. **314**(2): p. 145-52.
178. Li, W.L., et al., [*Retrovirus-mediated IL-18 gene expression in rat C6 glioma cell line*]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2004. **20**(5): p. 522-5.
179. Yamanaka, R., et al., *Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma*. J Neurooncol, 2005. **72**(2): p. 107-13.
180. Yamanaka, R. and K.G. Xanthopoulos, *Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18*. DNA Cell Biol, 2005. **24**(5): p. 317-24.
181. Hedtjarn, M., et al., *Combined deficiency of IL-1beta18, but not IL-1alpha18, reduces susceptibility to hypoxia-ischemia in the immature brain*. Dev Neurosci, 2005. **27**(2-4): p. 143-8.
182. Yamaoka-Tojo, M., et al., *C-reactive protein-induced production of interleukin-18 in human endothelial cells: a mechanism of orchestrating cytokine cascade in acute coronary syndrome*. Heart Vessels, 2003. **18**(4): p. 183-7.
183. Zaremba, J. and J. Losy, *Interleukin-18 in acute ischaemic stroke patients*. Neurol Sci, 2003. **24**(3): p. 117-24.
184. Reading, P.C. and G.L. Smith, *Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity*. J Virol, 2003. **77**(18): p. 9960-8.
185. Wald, D., et al., *IRAK and TAK1 are required for IL-18-mediated signaling*. Eur J Immunol, 2001. **31**(12): p. 3747-54.
186. Lee, J.K., et al., *Differences in signaling pathways by IL-1beta and IL-18*. Proc Natl Acad Sci U S A, 2004. **101**(23): p. 8815-20.
187. Takeda, K. and H. Ichijo, *Neuronal p38 MAPK signalling: an emerging regulator of cell fate and function in the nervous system*. Genes Cells, 2002. **7**(11): p. 1099-111.
188. Harris, C., A.C. Maroney, and E.M. Johnson, Jr., *Identification of JNK-dependent and -independent components of cerebellar granule neuron apoptosis*. J Neurochem, 2002. **83**(4): p. 992-1001.
189. Nelson, K.B., et al., *Neonatal cytokines and coagulation factors in children with cerebral palsy*. Ann Neurol, 1998. **44**(4): p. 665-75.
190. Minagawa, K., et al., *Possible correlation between high levels of IL-18 in the cord blood of pre-term infants and neonatal development of periventricular leukomalacia and cerebral palsy*. Cytokine, 2002. **17**(3): p. 164-70.
191. Ravizza, T., et al., *Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy*. Epilepsia, 2006. **47**(7): p. 1160-8.
192. Hoehn, T., et al., *Hyperoxia causes inducible nitric oxide synthase-mediated cellular damage to the immature rat brain*. Pediatr Res, 2003. **54**(2): p. 179-84.

193. Sirinyan, M., et al., *Hyperoxic exposure leads to nitrative stress and ensuing microvascular degeneration and diminished brain mass and function in the immature subject*. *Stroke*, 2006. **37**(11): p. 2807-15.
194. Bittigau, P., M. Sifringer, and C. Ikonomidou, *Antiepileptic drugs and apoptosis in the developing brain*. *Ann N Y Acad Sci*, 2003. **993**: p. 103-14; discussion 123-4.
195. Saugstad, O.D., *Resuscitation of newborn infants with room air or oxygen*. *Semin Neonatol*, 2001. **6**(3): p. 233-9.
196. Vento, M., et al., *Resuscitation with room air instead of 100% oxygen prevents oxidative stress in moderately asphyxiated term neonates*. *Pediatrics*, 2001. **107**(4): p. 642-7.